.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
Cantor Fitzgerald
UBS
Healthtrust
US Army
Dow
QuintilesIMS
Harvard Business School
Farmers Insurance

Generated: November 22, 2017

DrugPatentWatch Database Preview

Omacetaxine mepesuccinate - Generic Drug Details

« Back to Dashboard

What are the generic sources for omacetaxine mepesuccinate and what is the scope of omacetaxine mepesuccinate freedom to operate?

Omacetaxine mepesuccinate
is the generic ingredient in one branded drug marketed by Teva Pharms Intl and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Omacetaxine mepesuccinate has forty-nine patent family members in nineteen countries.

There are two drug master file entries for omacetaxine mepesuccinate. One supplier is listed for this compound.

Summary for omacetaxine mepesuccinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Intl
SYNRIBO
omacetaxine mepesuccinate
POWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Teva Pharms Intl
SYNRIBO
omacetaxine mepesuccinate
POWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Teva Pharms Intl
SYNRIBO
omacetaxine mepesuccinate
POWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Teva Pharms Intl
SYNRIBO
omacetaxine mepesuccinate
POWDER;SUBCUTANEOUS203585-001Oct 26, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: omacetaxine mepesuccinate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,613,900 Cephalotaxane derivatives and process for their preparation► Subscribe
7,842,687Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
7,169,774Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
6,831,180 Cephalotaxane derivatives and process for their preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: omacetaxine mepesuccinate

Country Document Number Estimated Expiration
Denmark2177223► Subscribe
France2776292► Subscribe
Poland343032► Subscribe
Denmark1443933► Subscribe
Japan2004523586► Subscribe
Hungary0101375► Subscribe
Cyprus1109799► Subscribe
Germany60234708► Subscribe
Austria548041► Subscribe
Hong Kong1067562► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
Baxter
Teva
Chubb
Medtronic
Covington
Accenture
Federal Trade Commission
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot